Every year, patients from the United States, Canada, the United Kingdom, Australia, and dozens of other countries travel to Germany seeking treatment for chronic Lyme disease. They come because the therapies they need are either unavailable or restricted in their home countries. They come because they have tried standard approaches and remain ill. And they come because Germany’s medical and regulatory environment supports a fundamentally different approach to this disease.
The Limitations of Standard Treatment Protocols
In the United States and many other countries, Lyme disease treatment guidelines are shaped by a framework that views the infection as straightforward and easily treatable with a short course of oral antibiotics. The Infectious Diseases Society of America (IDSA) guidelines recommend 2 to 4 weeks of doxycycline or amoxicillin for most cases of Lyme disease.
For patients diagnosed early with a single uncomplicated infection, this approach can be effective. But for the significant number of patients who develop chronic, persistent symptoms — often after delayed diagnosis, inadequate initial treatment, or the presence of co-infections — these short-course protocols consistently fail to resolve the disease.
Patients who remain symptomatic are frequently told that their Lyme disease has been “adequately treated” and that their ongoing symptoms must be attributed to something else. This leaves millions of patients without effective treatment options within their own healthcare systems.
Germany’s Different Approach
Germany’s medical regulatory environment permits a broader range of therapeutic approaches than many other countries. Licensed physicians operating within accredited medical facilities have the clinical freedom to employ combination treatments that address chronic Lyme disease as the complex, multi-systemic illness that it is. This includes:
- Extended antimicrobial protocols — Combination IV antibiotic regimens tailored to the individual patient’s infection profile and morphological forms of Borrelia
- Whole-body hyperthermia — Clinical-grade whole-body heating to 41.6–41.8 °C, which structurally compromises Borrelia spirochetes and dramatically increases antibiotic tissue penetration. This therapy is virtually unavailable outside of Germany
- Apheresis blood filtration — H.E.L.P. apheresis and therapeutic plasma exchange to remove circulating toxins, inflammatory mediators, and immune complexes from the bloodstream
- Photodynamic therapy — Light-activated antimicrobial treatment that reaches intracellular pathogens in tissues where antibiotics have limited penetration
- Comprehensive immune support — High-dose IV vitamin C, glutathione, thymus peptides, and micronutrient infusions to restore immune competence
The Advantage of Whole-Body Hyperthermia
Whole-body hyperthermia is, for many patients, the defining reason they travel to Germany. This therapy involves raising the patient’s core body temperature to 41.6–41.8 °C (106.9–107.2 °F) for approximately 120 minutes under continuous medical monitoring. At these temperatures, Borrelia spirochetes become structurally compromised and highly vulnerable to antibiotics administered concurrently.
The combination of thermal stress and antibiotic therapy is more effective than either approach alone. Hyperthermia reaches bacteria in deep tissue compartments where antibiotic concentrations are normally insufficient. It also activates heat shock proteins and stimulates immune responses that target the infection.
This level of clinical hyperthermia requires specialized equipment, trained medical staff, and an inpatient setting with full monitoring capabilities. Only a small number of hospitals worldwide offer this therapy, and Germany has the largest concentration of experienced providers.
What Patients Say
The decision to travel abroad for medical treatment is never taken lightly. Patients weigh the costs, the time away from work and family, and the uncertainty of outcomes. Yet for many, the results speak for themselves.
Patients frequently describe the experience of finally receiving a comprehensive treatment approach after years of fragmented, insufficient care at home. The structured inpatient setting, the daily physician contact, and the multimodal protocol targeting every aspect of the disease represent a fundamentally different standard of care.
The St. George Hospital Difference
St. George Hospital in Bad Aibling has been treating chronic infections using integrative medicine for over 35 years. Founded by Dr. Friedrich Douwes, the hospital pioneered many of the therapies now used for chronic Lyme disease in Germany. Today, under the medical leadership of Dr. Julian Douwes, the hospital continues to develop and refine its Lyme disease protocols.
What distinguishes St. George Hospital is the integration of multiple treatment modalities into a single, coordinated inpatient program. Rather than receiving one therapy at a time from different providers, patients at St. George receive a comprehensive treatment package: hyperthermia, antibiotics, apheresis, immune support, detoxification, and rehabilitation delivered together over a structured two- to five-week program.
The hospital has treated patients from more than 90 countries and maintains a dedicated international patient coordination team that assists with every aspect of the treatment journey, from initial consultation to post-discharge follow-up.